Pure Global AI
NCT06341985Recruiting

DOsimetry and Radiation Induced NAusea in Head and Neck Cancers

Prospective Multicenter Cohort Study for the Analysis of Correlation Between Dosimetric Parameters and RANV (Radiation Associated Nausea and Vomiting) in Patients With Head and Neck Cancer Undergoing Exclusive Radiotherapy (RT)
European Institute of OncologyClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Head and Neck Cancer
Drug/Device/Intervention
Exclusive radiotherapy
Study type
Observational
Intervention type
radiation
Sponsor & location
Primary sponsor
European Institute of Oncology
Location
Ancona,Barletta,Benevento,Castellanza,Genova,Milan,Milan,Modena,Novara,Pavia,Roma,Roma,Roma,Sesto San Giovanni, Italy
Timeline & enrollment
Phase
N/A
Start date
Nov 15, 2021
End date
Dec 31, 2024
Enrollment
180 participants
Primary outcome

Evaluation of nausea (acute toxicity) using CTCAE V5.0

Summary

This is a prospective cohort study for the analysis of correlation between dosimetric
 parameters and RANV (Radiation Associated Nausea and Vomiting) in patients with head and neck
 cancer undergoing exclusive radiotherapy (RT).
 
 The primary purpose of this study is to search for a potential correlation between dosimetry
 and physician- and patient-rated symptoms in patients treated with exclusive radiotherapy for
 head and neck cancer.

ICD-10 classifications
Malignant neoplasm of other and ill-defined sites: Head, face and neckMalignant neoplasm: Skin of scalp and neckMalignant neoplasm: Connective and soft tissue of head, face and neckCarcinoma in situ: Skin of scalp and neckSecondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06341985
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06341985 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.